Psilocybin and Mental Health: Who Should Not Use It
Psilocybin has an excellent physiological safety profile — no known lethal dose, no significant organ toxicity, no addiction potential. But psychological risks are real and specific. This guide identifies who should avoid psilocybin, what conditions require caution, and which medication interactions matter most.
The Summary
| Risk Category | Assessment | |---|---| | Personal history of psychosis | Hard contraindication — avoid | | Family history of schizophrenia | High caution — avoid without professional guidance | | Bipolar I disorder | Hard contraindication without clinical supervision | | Bipolar II disorder | Caution — professional guidance required | | Current lithium use | Avoid — seizure risk | | Current MAOI use | Avoid — serotonin syndrome risk | | SSRI/SNRI use | Significant reduction in effects — complex interaction | | Active major depression | Caution — benefit possible but set management required | | PTSD, active symptoms | Caution — can surface traumatic content | | Heart conditions | Medical review required | | Pregnancy | Avoid — no safety data |
Hard Contraindications
These are conditions under which psilocybin poses genuine serious psychological risk. They are not managed by "taking it carefully" or by sitter presence.
Schizophrenia and Psychotic Disorders
Psilocybin can precipitate psychotic episodes in people with schizophrenia or schizoaffective disorder. The mechanism is direct: psilocybin agonizes 5-HT2A receptors, which are implicated in psychosis pathophysiology, and in people with underlying vulnerability, the temporary psychedelic state can trigger longer-lasting psychotic episodes.
This is a hard stop. Clinical trials systematically exclude anyone with a personal or family history (first-degree relatives) of schizophrenia or psychotic disorders. No responsible facilitator should work with someone in this category.
Personal History of Psychosis
Even a single episode of psychosis — regardless of diagnosis — represents a vulnerability marker. This includes drug-induced psychosis from other substances. The prior episode indicates a system that can be pushed into psychotic states.
Bipolar I Disorder
High-dose psilocybin can trigger manic episodes in people with bipolar I. The intensity and duration of the manic trigger can exceed the psilocybin session itself. This is excluded from all clinical trials involving bipolar I patients.
High Caution: Conditions That Require Professional Guidance
Bipolar II Disorder
The risk profile is more nuanced than Bipolar I. Some clinicians work with bipolar II patients and psilocybin — carefully, with appropriate screening, preparation, and integration support. This is not a unilateral hard contraindication, but it absolutely requires professional psychiatric guidance. A solo or peer-guided experience with bipolar II is inappropriate.
Active Suicidal Ideation
Psilocybin can amplify distress in people who are already in significant psychological pain. A difficult session for someone with active suicidal ideation creates genuine risk of crisis escalation. If you are in acute suicidal crisis, psilocybin is not the appropriate tool at this moment. Resources: 988 Suicide and Crisis Lifeline, Fireside Project (62-FIRESIDE).
Note: This is different from chronic passive suicidal ideation as a depression symptom. Clinical trials have included patients with treatment-resistant depression who have experienced suicidal ideation — but under carefully controlled conditions with clinical oversight. The distinction matters.
Severe Trauma History with Active PTSD
Psilocybin sessions frequently surface traumatic material — this is often part of why they're therapeutic. But unsupported, unguided trauma surfacing can be re-traumatizing rather than healing. People with PTSD should engage with psilocybin in the context of trauma-informed support, not alone.
Medication Interactions
Lithium
Do not combine psilocybin with lithium under any circumstances. The combination is associated with significant seizure risk. This is not theoretical — there are documented cases. Anyone on lithium who wants to pursue psilocybin therapy should discuss medication management with their prescriber well in advance of any session. Tapering off lithium requires careful psychiatric supervision.
MAOIs (Monoamine Oxidase Inhibitors)
MAOIs potentiate serotonergic substances dangerously. Combining an MAOI with psilocybin risks serotonin syndrome — a potentially life-threatening condition involving excess serotonin activity (symptoms: agitation, confusion, rapid heart rate, high blood pressure, dilated pupils, muscle twitching, in severe cases seizures and hyperthermia).
MAOIs include: phenelzine, tranylcypromine, isocarboxazid (psychiatric MAOIs), selegiline (Parkinson's medication), and linezolid (antibiotic). St. John's Wort is also mildly MAO-inhibiting and should be discontinued before psilocybin use.
SSRIs and SNRIs
This is the most common medication interaction question and has a nuanced answer:
Psilocybin effects are significantly reduced by SSRIs/SNRIs because these medications downregulate 5-HT2A receptors over time — the same receptors psilocybin agonizes. People on SSRIs often find psilocybin produces minimal or no noticeable effects at typical doses.
Acute serotonin syndrome risk is low but not zero with SSRI+psilocybin combinations at therapeutic doses. The primary concern is receptor competition and blunted response rather than toxicity.
Tapering SSRIs to engage psilocybin therapy should only be done under psychiatric supervision. Abrupt SSRI discontinuation carries its own risks (discontinuation syndrome, depression relapse). Any medication management changes require a conversation with your prescriber.
Tramadol
Tramadol has both MAOI-like properties and serotonergic activity. Avoid combining with psilocybin.
Antipsychotics
Second-generation antipsychotics (quetiapine, risperidone, aripiprazole, etc.) block 5-HT2A receptors and will blunt or eliminate psilocybin effects. Combining them is unlikely to produce therapeutic benefit and creates unpredictable pharmacology.
Medical Conditions Requiring Caution
Cardiovascular Conditions
Psilocybin causes temporary elevation in heart rate and blood pressure during the session — typically modest, but relevant for people with unstable angina, recent cardiac events, hypertensive crisis history, or other significant cardiovascular disease. Medical review is appropriate before proceeding.
Seizure Disorders
The combination of psilocybin with seizure history requires neurological consultation. The seizure risk with psilocybin alone is very low, but the interaction with anti-epileptic medications and the underlying seizure threshold is poorly studied.
The Screening Question
All legitimate clinical trials and licensed service centers screen for these contraindications before admission. The screening process exists because these risks are real and have been identified through research and clinical experience.
If you're considering an unguided experience, the honest question to ask yourself is: would you pass the screening that a licensed service center or clinical trial would apply? If not — if you have psychosis history, bipolar I, active suicidal ideation, or you're on lithium or MAOIs — the answer is that this is not the right context for your psilocybin exploration.
When Psilocybin Might Still Be Appropriate (With Guidance)
Some conditions that seem like disqualifiers may be navigable with appropriate professional support:
- Treatment-resistant depression with passive suicidal ideation: Clinical trials include these patients under careful monitoring
- PTSD: Strong evidence base with trauma-informed facilitation
- Bipolar II with mood stability: Some practitioners work with this carefully
- SSRI use: Tapering is possible under supervision for motivated patients
The key distinction: unguided vs. professionally supported. Many of these situations that are inappropriate without support can be engaged with carefully through licensed service centers, clinical trials, or experienced harm reduction-oriented practitioners.
Resources
- Fireside Project: 62-FIRESIDE (623-473-7433) — crisis support
- 988 Suicide and Crisis Lifeline: 988 — crisis support
- TripSit Drug Interaction Checker: tripsit.me/combo — medication interactions
- MAPS Clinical Guidelines: maps.org — professional protocols
- Psychedelic Support: psychedelicsupport.com — vetted practitioners